GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma.

Tessa Gargett Lisa M EbertNga T H TruongParis M KollisKristyna SedivakovaWenbo YuErica C F YeoNicole L WittwerBriony L GliddonMelinda N TeaRebecca OrmsbySantosh PoonnooseJake NowickiOrazio VittorioDavid S ZieglerStuart M PitsonMichael P Brown

Published in: Journal for immunotherapy of cancer (2022)

Targeting GD2 using a clinically deployed CAR-T-cell therapy has a sound scientific and clinical rationale as a treatment for glioblastoma and other aggressive primary brain tumors.

Keyphrases

cell therapy
induced apoptosis
cancer therapy
poor prognosis
stem cells
mesenchymal stem cells
cell cycle arrest
binding protein
long non coding rna